2.1.1.184: 23S rRNA (adenine2085-N6)-dimethyltransferase
This is an abbreviated version!
For detailed information about 23S rRNA (adenine2085-N6)-dimethyltransferase, go to the full flat file.
Word Map on EC 2.1.1.184
-
2.1.1.184
-
macrolide
-
macrolide-lincosamide-streptogramin
-
methyltransferases
-
lincosamide
-
unmethylated
-
mtases
-
streptogramine
-
medicine
- 2.1.1.184
-
macrolide
-
macrolide-lincosamide-streptogramin
- methyltransferases
-
lincosamide
-
unmethylated
- mtases
-
streptogramine
- medicine
Reaction
2 S-adenosyl-L-methionine + = 2 S-adenosyl-L-homocysteine +
Synonyms
23S ribosomal RNA adenine N-6 methyltransferase, EC 2.1.1.48, ErmC, ermC 23 S rRNA methyltransferase, ErmC 23S rRNA methyltransferase, ermC methylase, ErmC methyltransferase, ErmC', ErmC' methyltransferase, ErmC' MTase, erythromycin resistance protein, rRNA methyltransferase ErmC', rRNA:m6A methyltransferase ErmC'
ECTree
Advanced search results
Inhibitors
Inhibitors on EC 2.1.1.184 - 23S rRNA (adenine2085-N6)-dimethyltransferase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
2-([[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl][3-(1H-imidazol-1-yl)propyl]amino]methyl)-1H-isoindole-1,3(2H)-dione
i.e. PD00556
N6-dimethyladenine2085 containing 23S rRNA
linear competitive inhibition kinetics with RNA as the variable substrate, mixed inhibition with S-adenosyl-L-methionine as the variable substrate
-
nicotinaldehyde-N-[3-(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl]hydrazone
i.e. HTS12610
additional information
the crystal structure of ErmC methyltransferase is used as a target for structure-based virtual screening of a database composed of 58679 lead-like compounds. Among 77 compounds selected for experimental validation (63 predicted to bind to the catalytic pocket and 14 compounds predicted to bind to the putative RNA binding site), several novel inhibitors are found that decrease the minimal inhibitory concentration of a macrolide antibiotic erythromycin toward an Escherichia coli strain that constitutively expresses ErmC'. Analysis of docking models of the identified inhibitors suggests a novel strategy to develop potent and clinically useful inhibitors
-
linear competitive pattern with S-adenosyl-L-methionine as the variable substrate, and a mixed inhibition kinetics with RNA